Figure 3.
Current EFS for patients receiving imatinib as initial therapy for CML-CP.10 CEFS, current event-free survival.

Current EFS for patients receiving imatinib as initial therapy for CML-CP.10  CEFS, current event-free survival.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal